Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis: A real-world disproportionality and machine learning analysis.
Moon J, Lee C, Lee S, Kim M, Wen X, Branda F, Oh J, Son Y, Lee K, Choi T, Yon DK
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.